Exscientia (EXAI) Competitors $4.84 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends EXAI vs. ABCL, RLAY, SDGR, RXRX, CPRX, IOVA, TWST, LBPH, ARWR, and PTGXShould you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include AbCellera Biologics (ABCL), Relay Therapeutics (RLAY), Schrödinger (SDGR), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), Longboard Pharmaceuticals (LBPH), Arrowhead Pharmaceuticals (ARWR), and Protagonist Therapeutics (PTGX). These companies are all part of the "medical" sector. Exscientia vs. AbCellera Biologics Relay Therapeutics Schrödinger Recursion Pharmaceuticals Catalyst Pharmaceuticals Iovance Biotherapeutics Twist Bioscience Longboard Pharmaceuticals Arrowhead Pharmaceuticals Protagonist Therapeutics Exscientia (NASDAQ:EXAI) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking. Does the media refer more to EXAI or ABCL? In the previous week, Exscientia had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Exscientia and 1 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.62 beat Exscientia's score of 0.34 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exscientia 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community favor EXAI or ABCL? AbCellera Biologics received 42 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 75.71% of users gave AbCellera Biologics an outperform vote while only 37.93% of users gave Exscientia an outperform vote. CompanyUnderperformOutperformExscientiaOutperform Votes1137.93% Underperform Votes1862.07% AbCellera BiologicsOutperform Votes5375.71% Underperform Votes1724.29% Do institutionals and insiders believe in EXAI or ABCL? 41.6% of Exscientia shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 16.4% of Exscientia shares are owned by company insiders. Comparatively, 28.0% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, EXAI or ABCL? AbCellera Biologics has higher revenue and earnings than Exscientia. AbCellera Biologics is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExscientia$25.60M24.72-$181.56M-$1.51-3.21AbCellera Biologics$38.03M20.74-$146.40M-$0.61-4.38 Which has more volatility and risk, EXAI or ABCL? Exscientia has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Do analysts recommend EXAI or ABCL? Exscientia currently has a consensus price target of $7.00, indicating a potential upside of 44.63%. AbCellera Biologics has a consensus price target of $8.67, indicating a potential upside of 224.59%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Exscientia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exscientia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is EXAI or ABCL more profitable? AbCellera Biologics has a net margin of -533.32% compared to Exscientia's net margin of -882.09%. AbCellera Biologics' return on equity of -15.73% beat Exscientia's return on equity.Company Net Margins Return on Equity Return on Assets Exscientia-882.09% -49.10% -33.13% AbCellera Biologics -533.32%-15.73%-12.22% SummaryAbCellera Biologics beats Exscientia on 14 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Exscientia News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAI vs. The Competition Export to ExcelMetricExscientiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$632.93M$2.94B$5.01B$8.81BDividend YieldN/A1.89%5.21%4.07%P/E Ratio-3.2143.12126.5217.52Price / Sales37.08359.351,203.9085.12Price / CashN/A160.0933.3732.51Price / Book1.323.734.684.68Net Income-$181.56M-$41.63M$118.36M$225.62M7 Day Performance-13.73%-7.94%-2.46%-2.04%1 Month Performance-7.10%-7.19%-4.06%0.03%1 Year Performance-16.84%23.01%29.55%24.47% Exscientia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXAIExscientia1.9994 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$25.60M-3.21280News CoverageABCLAbCellera Biologics2.9915 of 5 stars$2.67-1.5%$8.67+224.6%-42.0%$788.64M$38.03M-4.38586Positive NewsRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeSDGRSchrödinger1.9918 of 5 stars$19.17+1.3%$32.90+71.6%-37.1%$1.38B$216.67M0.00867RXRXRecursion Pharmaceuticals1.9971 of 5 stars$6.04-3.7%$9.25+53.1%-12.0%$1.80B$44.58M0.00400Analyst ForecastOptions VolumeHigh Trading VolumeCPRXCatalyst Pharmaceuticals4.7417 of 5 stars$21.15-1.1%$31.14+47.2%+54.3%$2.52B$398.20M17.92167Analyst ForecastIOVAIovance Biotherapeutics4.0475 of 5 stars$8.14-0.6%$22.33+174.4%+48.3%$2.50B$1.19M0.00500Options VolumeTWSTTwist Bioscience4.1398 of 5 stars$41.11-0.5%$51.78+25.9%+66.2%$2.45B$312.97M0.00990Analyst ForecastAnalyst RevisionLBPHLongboard Pharmaceuticals1.4685 of 5 stars$59.77-0.1%$59.56-0.4%+1,283.6%$2.34BN/A0.0020ARWRArrowhead Pharmaceuticals3.5698 of 5 stars$18.71+0.6%$45.33+142.3%-35.3%$2.31B$240.74M0.00400Upcoming EarningsAnalyst ForecastPTGXProtagonist Therapeutics3.0192 of 5 stars$40.65+5.2%$53.57+31.8%+135.8%$2.30B$60M15.28125Analyst ForecastNews Coverage Related Companies and Tools Related Companies AbCellera Biologics Competitors Relay Therapeutics Competitors Schrödinger Competitors Recursion Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Twist Bioscience Competitors Longboard Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EXAI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
